STEM CELLS AND AGEING
干细胞与衰老
基本信息
- 批准号:7121494
- 负责人:
- 金额:$ 24.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-15 至 2009-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The hypothesis that bone marrow stem cells are a determining factor in ageing will be tested in a mouse model of premature ageing. First, the number and homing capacity of bone marrow stem cells from wild type p53+/+ and premature ageing p53+/m C57BL/6J mice will be assayed in vitro and in vivo. Then, both the ability of wild-type bone marrow stem cells to correct premature ageing in p53+/m mutant mice, and the ability of bone marrow stem cells from premature ageing p53+/m mutant mice to induce premature ageing, in wild-type recipients will be determined. In Specific Aim 1, the number of stem cells in wild-type p53+/+, p53+/- and p53+/m mice will be determined by flow cytometry and by in vitro colony formation, and homing determined by in vitro migration and marrow repopulation in vivo. In Specific Aim 2 bone marrow cells from GFP+ male C57BI6 p53+/+ mice will be transplanted to p53 mutant (p53+/m) and to wild-type (p53 +/+) female mice and the effect on the development of the aging phenotype determined. The contribution of donor cells to recipient tissues will be identified by the presence of GFP and the Y-chromosome. If ageing is due to a decreased ability of bone marrow stem cells to contribute to replacement of normal tissues in this model, transplantation of bone marrow cells from normal mice to p53 mutant mice should restore normal phenotype and normal life span. In Specific Aim 3 bone marrow cells from GFP+ p53+/m male mutant mice will be transplanted to irradiated normal wild-type female mice and to female mutant mice to determine if the aging phenotype can be transferred mutant bone marrow stem cells. Finally the possibility of fusion of donor bone marrow cells with tissue cells of recipient mice and the presence of fused cells in tumors will be determined. The results of these experiments should provide critical proof for one of the most important hypothetical properties of adult stem cells.
描述(由申请人提供):骨髓干细胞是衰老决定因素的假设将在小鼠早衰模型中进行测试。首先,在体外和体内检测野生型p53+/+和早衰型p53+/m C57BL/6J小鼠骨髓干细胞的数量和归巢能力。然后,将确定野生型骨髓干细胞在p53+/m突变小鼠中纠正过早衰老的能力,以及来自过早衰老p53+/m突变小鼠的骨髓干细胞在野生型受体中诱导过早衰老的能力。在Specific Aim 1中,野生型p53+/+、p53+/-和p53+/m小鼠的干细胞数量将通过流式细胞术和体外集落形成来确定,并通过体外迁移和体内骨髓再生来确定归巢。在Specific Aim 2中,将来自GFP+雄性C57BI6 p53+/+小鼠的骨髓细胞移植到p53突变型(p53+/m)和野生型(p53+/ +)雌性小鼠身上,并测定其对衰老表型发展的影响。供体细胞对受体组织的贡献将通过GFP和y染色体的存在来识别。如果在这个模型中,衰老是由于骨髓干细胞替代正常组织的能力下降,那么将正常小鼠的骨髓细胞移植到p53突变小鼠身上应该可以恢复正常的表型和正常的寿命。在Specific Aim 3中,将来自GFP+ p53+/m雄性突变小鼠的骨髓细胞移植到辐照的正常野生型雌性小鼠和雌性突变小鼠中,以确定衰老表型是否可以转移突变骨髓干细胞。最后,将确定供体骨髓细胞与受体小鼠组织细胞融合的可能性以及融合细胞在肿瘤中的存在。这些实验的结果应该为成人干细胞最重要的假设特性之一提供关键证据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEWART SELL其他文献
STEWART SELL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEWART SELL', 18)}}的其他基金
Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
黄曲霉毒素 B1 在 mGSTA3-/- 小鼠中的肝癌发生
- 批准号:
8827703 - 财政年份:2012
- 资助金额:
$ 24.36万 - 项目类别:
Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
黄曲霉毒素 B1 在 mGSTA3-/- 小鼠中的肝癌发生
- 批准号:
9031727 - 财政年份:2012
- 资助金额:
$ 24.36万 - 项目类别:
Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
黄曲霉毒素 B1 在 mGSTA3-/- 小鼠中的肝癌发生
- 批准号:
8629710 - 财政年份:2012
- 资助金额:
$ 24.36万 - 项目类别:
Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
黄曲霉毒素 B1 在 mGSTA3-/- 小鼠中的肝癌发生
- 批准号:
8293559 - 财政年份:2012
- 资助金额:
$ 24.36万 - 项目类别:
Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
黄曲霉毒素 B1 在 mGSTA3-/- 小鼠中的肝癌发生
- 批准号:
8464677 - 财政年份:2012
- 资助金额:
$ 24.36万 - 项目类别:
相似海外基金
Prevention of age-related hearing loss using bone marrow transplantation
利用骨髓移植预防与年龄相关的听力损失
- 批准号:
23K08999 - 财政年份:2023
- 资助金额:
$ 24.36万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Bone Marrow Transplantation Approach for Sickle Cell Disease Using Targeted Marrow Irradiation
使用靶向骨髓照射治疗镰状细胞病的新型骨髓移植方法
- 批准号:
10737358 - 财政年份:2023
- 资助金额:
$ 24.36万 - 项目类别:
Tuning tyrosine kinase signalling to improve haematopoietic stem cell expansion and bone marrow transplantation
调节酪氨酸激酶信号传导以改善造血干细胞扩增和骨髓移植
- 批准号:
2889841 - 财政年份:2023
- 资助金额:
$ 24.36万 - 项目类别:
Studentship
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
- 批准号:
10722602 - 财政年份:2022
- 资助金额:
$ 24.36万 - 项目类别:
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
- 批准号:
10368246 - 财政年份:2022
- 资助金额:
$ 24.36万 - 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
- 批准号:
10600143 - 财政年份:2022
- 资助金额:
$ 24.36万 - 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
- 批准号:
10370775 - 财政年份:2022
- 资助金额:
$ 24.36万 - 项目类别:
The mycobiota, bone marrow transplantation, and clinical outcomes
真菌群、骨髓移植和临床结果
- 批准号:
10415200 - 财政年份:2021
- 资助金额:
$ 24.36万 - 项目类别:
The mycobiota, bone marrow transplantation, and clinical outcomes
真菌群、骨髓移植和临床结果
- 批准号:
10303678 - 财政年份:2021
- 资助金额:
$ 24.36万 - 项目类别:














{{item.name}}会员




